An Overview
pathSCORE
Breast cancer is one of the most common cancers In women world-wide
with numbers expected to Increase as the
population ages. A focus of Healthcare systems is rapid and accurate
diagnosis, which drives optimal treatment planning. The world-wide
market for such diagnoses is already huge and will grow.
A central element of diagnosis is the histopathological assessment of
tissue biopsies. This subjective assessment is open to modernisation and
automation to improve reliability, screening throughput and exchange of
data. pathSCORE is a PC software-based approach that delivers these
improvements. It has been developed by QinetiQ in conjunction with
academic and healthcare experts, and validated against existing data.
pathSCORE operates on a number of synergistic levels to enhance and
standardise pathologists' diagnoses.
Image Digitisation and Compression
Microscope images of histopathological slides of tissue biopsies are captured into digital files. To facilitate, use and transmit these very large data files, patented novel QinetiQ Image-compression techniques are used to reduce file size without loss of diagnostic Information. Images can be edited to highlight and annotate key features as an aid to improve diagnosis traceability, without loss of original raw data.
Automatic histopathological data analysis
Using automatic software detection and grading of diagnostic parameters (including cerbB2 status, facilitating targeted treatment with herceptin) digital images are rapidly and reproducibly assessed for management review.
Telepathology
Original digital Images, together with highlights and annotations, can be transmitted over standard telecommunication networks for discussion, case-conferences, review, research or storage as required.
Histopathological Database
This is an Interactive web-based database which could be hospital, area, country or even internationally focused In operation. The database enables remote storage, searching, indexing and retrieval, together with automatic analysis of histopathology slides.
Building on the validated utility of pathSCORE in breast cancer will involve extrapolation to other solid tumour diagnosis, starting with prostate cancer. Again this market is large and there is a need to modernise and automate. vivoMEDICA's collaboration with academic and healthcare groups will initially identify diagnostic indicators, both presently and in the near future, before pathSCORE is reoriented towards automatic detection and grading of those indicators
pathSCORE visits Glasgow:
pathSCORE presents at Glasgow pathology conference.....
>> more info01 Oct - 31 Oct
Breast Cancer Awareness Month
>> Breakthrough Breast Cancer